Patients with non–small cell lung cancer (NSCLC), carrying a MET splicing variant resulting in exon 14 skipping (METex14 skipping) mutations and impaired receptor breakdown, are responsive to small molecule inhibitors of MET (7). This evidence concerns the gene MET and lung cancer.